Differences Between Women and Men Taking a Combination of Indinavir, Ritonavir, Enteric-Coated Didanosine, and Stavudine Who Previously Took Anti-HIV Drugs
A Study of the Combination of Indinavir, Ritonavir, Enteric-Coated ddI and d4T In Nucleoside and Non-Nucleoside Reverse Transcriptase Inhibitor Experienced Patients: An Open-Label Study Investigating Differences Between Women and Men
Sponsor: PPD Development, LP
A PHASE3 clinical study on HIV Infections, this trial is ongoing. The trial is conducted by PPD Development, LP and has accumulated 7 data snapshots since 2000. Infectious disease trials contribute critical data for public health response and treatment development.
Change History
7 versions recorded-
Jun 2025 — Present [monthly]
Unknown PHASE3
-
Oct 2024 — Jun 2025 [monthly]
Unknown PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
▶ Show 2 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE3
First recorded
Aug 2000
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- PPD Development, LP
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Berkeley, United States, Boston, United States, Dallas, United States, Fort Lauderdale, United States, Los Angeles, United States, Nashville, United States, New Orleans, United States, New York, United States, Newark, United States, Ponce, Puerto Rico and 3 more location s